On Friday, analysts from StockNews.com initiated coverage on the shares of Aspira Women’s Health (NASDAQ:AWH – Get Free Report), assigning a “hold” rating to the stock.
Price Performance of Aspira Women’s Health
On the opening of trading last Friday, shares of NASDAQ:AWH were priced at $0.70. The company boasts a market capitalization of $11.67 million, a price-to-earnings ratio of -0.58, and a beta rating of 1.39. Aspira Women’s Health experienced a 12-month low of $0.67 and a high of $5.65 during the same period. Currently, its 50-day moving average stands at $0.83, while the 200-day moving average is $1.14.
Institutional Holdings in Aspira Women’s Health
Recently, an institutional investor made a notable move by acquiring shares of Aspira Women’s Health. According to a Form 13F filing with the SEC, Pine Valley Investments Ltd Liability Co bought 31,200 shares valued at approximately $25,000 during the third quarter. As of the latest filing, Pine Valley Investments owned about 0.19% of Aspira Women’s Health. In total, institutional investors hold approximately 12.19% of the company’s shares.
Overview of Aspira Women’s Health
Aspira Women’s Health Inc, along with its subsidiaries, focuses on the discovery, development, and commercialization of noninvasive diagnostic tests powered by AI, specifically for gynecological diseases in the United States. Their product lineup includes Ova1Plus, a qualitative serum test aimed at evaluating the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test designed to enhance Ova1’s high sensitivity; and OvaWatch, a laboratory-developed test intended to aid in the initial evaluation of malignancy risks in women presenting with indeterminate or benign adnexal masses.
Receive Daily Updates on Aspira Women’s Health
Stay Informed and Empowered – Subscribe below for a daily summary of the latest news and analysts’ ratings for Aspira Women’s Health and similar companies with MarketBeat.com’s FREE daily email newsletter.
